Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 4077 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

OrthoLogic acquires Azerx compound for $8 million

AZX100 is currently being investigated for indications such as the treatment of vasospasm associated with subarachnoid hemorrhage, the prevention of keloid scarring, and the treatment of asthma. Preclinical

Algeta drug shows promise in phase II trial

Algeta, headquartered in Norway, is conducting the trial as part of its phase II clinical program for Alpharadin, a novel radiopharmaceutical based on the alpha particle emitter radium-223,

Caraco gets go-ahead for generic Luvox

The tablets are a generic version of the active ingredient found in Luvox which was formerly marketed by Solvay Pharmaceuticals. However, the Luvox brand is no longer available

Arisaph grants license for diabetes patents

Arisaph received a significant upfront payment upon execution and will receive development milestone payments and a royalty on sales. Additional financial terms were not disclosed. “We are extremely

Teva’s generic Zofran gets provisional FDA approval

The product is specifically indicated for prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin, and prevention of postoperative